Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $29.4 million.

  • Protalix BioTherapeutics' Cash & Current Investments rose 715.46% to $29.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.4 million, marking a year-over-year increase of 715.46%. This contributed to the annual value of $34.8 million for FY2024, which is 2183.57% down from last year.
  • Protalix BioTherapeutics' Cash & Current Investments amounted to $29.4 million in Q3 2025, which was up 715.46% from $33.4 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Cash & Current Investments' 5-year high stood at $76.9 million during Q2 2021, with a 5-year trough of $20.8 million in Q3 2022.
  • Over the past 5 years, Protalix BioTherapeutics' median Cash & Current Investments value was $34.8 million (recorded in 2024), while the average stood at $40.0 million.
  • In the last 5 years, Protalix BioTherapeutics' Cash & Current Investments skyrocketed by 11989.14% in 2021 and then crashed by 6286.2% in 2022.
  • Protalix BioTherapeutics' Cash & Current Investments (Quarter) stood at $39.0 million in 2021, then plummeted by 43.11% to $22.2 million in 2022, then skyrocketed by 100.9% to $44.6 million in 2023, then decreased by 21.84% to $34.8 million in 2024, then fell by 15.68% to $29.4 million in 2025.
  • Its Cash & Current Investments stands at $29.4 million for Q3 2025, versus $33.4 million for Q2 2025 and $34.7 million for Q1 2025.